Fluorescent Arylphosphonic Acids: Synergic Interactions between Bone and the Fluorescent Core

Yunus Zorlu,[a] Connor Brown,[b] Claudia Keil,[c] M. Menaf Ayhan,[a] Hajo Haase,[c] Richard B. Thompson,[d] Imre Lengyel,[b] and Gündoğ Yücesan*[e][c]

Abstract: Herein, we report the third generation of fluorescent probes (arylphosphonic acids) to target calcifications, particularly hydroxyapatite (HAP). In this study, we use highly conjugated porphyrin-based arylphosphonic acids and their diesters, namely 5,10,15,20-tetrakis[8-(diethoxysilyl)phenyl]porphyrin (m-H$_8$TPPA-OEt) and 5,10,15,20-tetrakis[8-(m-phenylphosphonic acid)porphyrin (m-H$_8$TPPA), in comparison with their positional isomers 5,10,15,20-tetrakis[8-(diisopropoxyphosphoryl)phenyl]porphyrin (p-H$_8$TPPA-Pr$_8$) and 5,10,15,20-tetrakis[p-phenylphosphonic acid]porphyrin (p-H$_8$TPPA), which have phosphonic acid units bonded to sp$^2$ carbon atoms of the fluorescent core. The conjugation of the fluorescent core is thus extended to the (HAP) through sp$^2$-bonded –PO$_3$H$_2$ units, which generates increased fluorescence upon HAP binding. The resulting fluorescent probes are highly sensitive towards the HAP in rat bone sections. The designed probes are readily taken up by cells. Due to the lower reported toxicity of (p-H$_8$TPPA), these probes could find applications in monitoring bone resorption or adsorption, or imaging vascular or soft tissue calcifications for breast cancer diagnosis etc.

Dysregulation of calcium and phosphate homeostasis often leads to the pathological deposition of minerals, such as calcium carbonate (CC), calcium oxalate (CO), calcium phosphate (CP), calcium pyrophosphate (CPP), and hydroxyapatite (HAP) in many soft tissues, [1-4] such as those in the brain, [5-8] eye, [9-11] kidney [12,13] and skin. [14,15] The pathological deposition of these minerals causes these tissues to become inflexible or even brittle, which can lead to uncontrolled access of extracellular materials or prevent the passive diffusion of molecules between cells and their environment, likely leading to cell death. [12] In addition, minerals like HAP can facilitate the retention of molecules by providing a binding surface for the pathological accumulation of molecules. [13] Detecting and monitoring increased calcification can be a valuable early indication of breast cancer. [14] Conversely, monitoring the decrease in mineralization can be useful for assessing osteoporosis. [15] In addition, evidence is emerging that HAP deposition may play a role in the development and progression of age-related macular degeneration in the retina and neurodegeneration in the brain. [16] Therefore, monitoring calcification in health and disease is critical for diagnosis, monitoring progression and treatment.

There are several methods used to monitor calcification, some applicable in vivo while others only work in vitro. [17,18] A number of radiological techniques have the potential to detect calcification using radiography, [19,20] fluoroscopy, [19] conventional computed tomography (CT), [21] electron-beam tomography (EBT), [22] multi-detector CT (MDCT), [17,20] intravascular ultrasound, [19,20] magnetic resonance imaging (MRI), [21] and transthoracic echocardiography. [22] However, most current methods cannot resolve smaller than millimeter sized mineralization and are usually invasive, costly and not well tolerated. [23] In vitro, the resolution can be significantly increased: The classic Von Kossa histochemical method relies on silver precipitation at sites of phosphate deposition, [24] while Alizarin Red S, a colorimetric label, is widely used to detect calcium deposition. [25] In combination these are effective, inexpensive and widely used methods to detect calcium phosphate mineralization in fixed cells in culture or postmortem tissue sections, but they are not very sensitive and subcellular resolution is limited.

Supporting information and the ORCID identification number(s) for the author(s) of this article can be found under:
https://doi.org/10.1002/chem.202001613. It contains detailed synthetic procedures, FTIR, MALDI-MS, UV/Vis, fluorescent spectra, 1H NMR, 31C NMR, and 31P NMR. In addition, more detailed images of rat bone sections are included.

© 2020 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim

This is an open access article under the terms of the Creative Commons Attribution Non-Commercial NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Fluorescent probes broadly offer better sensitivity than colorimetric ones, but existing stains such as Alizarin Red S, Xylenol Orange, or uranium have clear drawbacks such as modest selectivity among mineral phases, pH dependence, overlap of their fluorescence with tissue autofluorescence. Frangioni and Kovar’s research groups developed the second generation fluorescent probes coupling HAP-binding moieties such as bisphosphonate or tetracycline with red and near-infrared penta- or hepta-methylene cyanine fluorescent moieties; the longer wavelength excitation and emission of these fluorophores substantially reduces scattering and background fluorescence.[26–28] These probes were sensitive, selective, and usable in vivo in animal models, but are costly and by comparison with other probes that exhibit significant or unique changes in fluorescence when binding to particular targets such as DNA (dansylamide) with carbonic anhydrase,[29] the triphenyl methane dye Auramine O with LADH (horse liver alcohol dehydrogenase) with,[30] or ethidium bromide with DNA,[31] their fluorescence is insensitive to whether they have bound to the (calfed) target or nonspecifically to something else. To address this latter issue, we sought to develop the third generation of fluorescent probes of calcification bearing phosphonic acid metal binding units which are bonded to one of the sp³ carbon atoms of the fluorescent cores, with the goal of differentially perturbing the fluorescence of the probe when bound to calcified substrates, and thereby providing additional information. The use of such fluorophores would be important with respect to generating synergic interactions between the fluorescent core and the d orbitals of the target divalent metal ions.

In this sense, the phosphonic acid metal binding group has recently attracted significant attention in diverse scientific fields ranging from material science to medicine.[32, 33] Our initial toxicity studies with aromatic phosphonic acids and phosphonate metal-organic solids were promising for their in vivo applications inasmuch as p-H₄TPPA exhibited no toxicity for an intestinal cell line at high concentrations.[34, 35] One of the unexplored properties of phosphonic acid metal binding groups is their potential role in imaging metal deposits in living systems. Our and Demadis’ recent work, and Martell’s early work from the 1970s all indicate that phosphonates exhibit high affinity towards alkaline and alkaline earth metal ions, as well as divalent transition-metal ions.[35–39] In addition, the pKₐ of phenylphosphonic acid (PhPONO₂H) is 7.44, giving PhPONO₂⁻ a –2 charge under physiological pH.[40] Therefore, the use of phosphonic acid metal-binding unit(s) to target biologically significant divalent metal ions offers highly sensitive and pH-independent metal probes working near physiological pH. Bisphosphonates have been previously attached to cyanine (Osteosense®) and fluorescein moieties with long aliphatic hydrocarbon side chains to label target calcification with green or near infrared fluorescence.[39, 41] The presence of sp³ bonds in the aliphatic linker chain in these examples between the phosphonic acid and the fluorescent core in these examples merely used bisphosphonates as recognition moieties and minimized any electronic interactions between the fluorescent core and the phosphonic acid metal binding unit. Therefore, such fluorescent labels provide little if any change in fluorescence intensity upon HAP binding.[39, 41–43] By comparison, the direct conjugation of phosphonic acid metal binding group with an sp³ carbon atom of the fluorescent core extends the conjugation of the fluorescent core up to the coordinated metal ion. Thus, it offers the prospect of the metal-ion binding the phosphonate and affecting the fluorescence in useful ways. For instance, such binding and recognition of a metal ion might cause useful changes in fluorescence that might help discriminate metal-bound fluorophores from unbound or non-specifically bound fluorophores. Such fluorescent phosphonates containing direct sp³ conjugation with the fluorescent core have not been reported in the literature, perhaps due to synthetic difficulties and the high energy requirement to form P–C bonds. Our recent research efforts with arylyphosphonic acid synthesis have generated novel strategies to introduce phosphonic acid around aromatic scaffolds, by Suzuki cross coupling or the d-catalyzed Arbuzov reaction.[44–47]

For this study, as seen in Scheme 1, we have synthesized 4 fluorescent probes. Two of them incorporate phenylphosphonic acid as the HAP binding unit with highly conjugated porphyrin cores, namely 5,10,15,20-tetrakis(p-phenylphosphonic acid)-porphyrin (p-H₄TPPA) and 5,10,15,20-tetrakis(m-phenylphosphonic acid)porphyrin (m-H₄TPPA) (Figure 1; please see the Supporting Information for synthesis details). p-H₄TPPA has four para-positioned PPA units promoting direct conjugation between the HAP and the fluorescent core. On the other hand, m-H₄TPPA has four meta-positioned PPA units creating a more protective environment between the fluorescent porphyrin core and the HAP. We then explored their potential for binding hydroxyapatite. As a control group we used the isopropylidest- and ethylidest analogues of p-H₄TPPA and m-H₄TPPA, namely p-H₄TPPA-iPr₆ and m-H₄TPPA-OEt₆ (see the Supporting

Scheme 1. The fluorescent probes used in this study: A) 5,10,15,20-Tetra-kis[p-(diisopropoxyphosphoryl)phenyl]porphyrin (p-H₄TPPA-iPr₆), B) 5,10,15,20-Tetra-kis[p-(phenylphosphonic acid)porphyrin (p-H₄TPPA), B) 5,10,15,20-Tetra-kis[p-(diethoxyphosphoryl)phenyl]porphyrin (m-H₄TPPA-iPr₆), C) 5,10,15,20-Tetra-kis[m-(diethoxyphosphoryl)phosphoryl]porphyrin (m-H₄TPPA-OEt₆), D) 5,10,15,20-Tetra-kis[m-(phenylphosphonic acid)porphyrin (m-H₄TPPA).
A previous synthesis of \( \text{p-H}_4\text{TPPA} \) relied on the Ni-catalyzed Arbusov reaction. Therefore, \( \text{p-H}_4\text{TPPA} \) that is synthesized using this route usually has Ni bound to the nitrogens in the porphyrin core. In this study, we have used an alternative method using Pd-catalyzed Arbusov reaction to obtain metal free \( \text{p-H}_4\text{TPPA} \). (please see the Supporting Information for synthesis details, NMR, FTIR spectra, and the crystallographic tables).

To probe their HAP binding properties in a biological matrix, we have used cross sectioned mouse ribs as an example for natural occurring HAP. The sections were incubated with \( \text{p-H}_4\text{TPPA}, \text{m-H}_4\text{TPPA} \) and \( \text{p-H}_4\text{TPPA}-\text{iPr}_8 \) at concentrations ranging from 0.01 to 1.0 mg mL\(^{-1}\) in HEPES buffer for varying times at room temperature, then imaged by fluorescence microscopy (details below in the figure legends), to assess HAP binding capability. Ribs incubated with 1 mg mL\(^{-1}\) \( \text{p-H}_4\text{TPPA} \) showed a greater fluorescence intensity than both 0.1 mg mL\(^{-1}\) and 0.01 mg mL\(^{-1}\) (Figure S17A–C, respectively), whilst still showing clear fluorescence signal at the lowest concentration of 0.1 mg mL\(^{-1}\) used here.

This indicates that the dye binding to HAP is concentration dependent. When the mouse ribs were incubated with 1 mg mL\(^{-1}\) \( \text{p-H}_4\text{TPPA} \) in HEPES for differing times from 120 to 289 mins, there was a clear decrease in fluorescence intensity but even the 10 min short incubation yielded an appreciable fluorescence compared to the negative control (Figure S18E compared to Figure S17F). When ribs were incubated with \( \text{p-H}_4\text{TPPA} \) diluted to 1 mg mL\(^{-1}\) in different buffers, there was no clear difference between the fluorescence intensity of HEPES, PBS, TBS (Figure S19A–C, respectively). However, when \( \text{p-H}_4\text{TPPA} \) was diluted in \( \text{dH}_2\text{O} \) (Figure S19D), there was no fluorescent signal observed. Sections were re-imaged at several time points after the original microscopy sessions to observe the stability of labeling. There was a noticeable decrease in fluorescence intensity in all of the solvents although signal diminished faster in HEPES buffer than in PBS or TBS (Figure S20). At the two week time point there was still a weak fluorescent signal observed for \( \text{p-H}_4\text{TPPA} \) diluted in PBS, but not for the other buffers (Figure S20N compared to Figure S20O). No signal was associated with incubating the ribs with the solvents as a negative control (Figure S20Q–T).

The phosphonic acid moieties in \( \text{m-H}_4\text{TPPA} \) are more protected compared to the \( \text{para} \)-positioned \( \text{p-H}_4\text{TPPA} \). When mouse ribs were incubated with different concentrations of \( \text{m-H}_4\text{TPPA} \) (1 to 0.01 mg mL\(^{-1}\) in HEPES buffer) we found little to no difference in the fluorescence intensities (Figure S21A–C, respectively). When the mouse ribs were incubated with 1 mg mL\(^{-1}\) \( \text{m-H}_4\text{TPPA} \) in HEPES for differing times, 10 to 120 mins, there were no appreciable difference in fluorescence intensities at the different incubation times (Figure S22A–E, respectively) while the fluorescent intensities were clearly distinguishable from HEPES alone (Figure S22F). Imaging of the sections were repeated two weeks following the original microscopy sessions to find no noticeable decrease in fluorescence intensity between ribs incubated with 1 mg mL\(^{-1}\) \( \text{m-H}_4\text{TPPA} \) in HEPES buffer and imaged on the day of staining compared with images taken 4, 7 and 14 days later (Figure 1F–I, respectively). This is a noticeable difference compared to \( \text{p-H}_4\text{TPPA} \), with a less protected structure, where there is a loss of fluorescent signal with increasing time after initial staining (Figure 1A–D, respectively). This could be associated with the more protected HAP phosphonic acid interaction in the \( \text{meta} \) position limiting the interactions with the surrounding molecules buffers etc. Again, no signal was associated with incubating the ribs with HEPES only as a negative control (Figure 1E and I, respectively).

As seen in Figure 2, the absorbance peak (Figure 2A) of \( \text{p-H}_4\text{TPPA} \) in PBS, TBS and HEPES with the addition of HAP corre-
Figure 2. The absorbance (A) and fluorescence (B) spectra of 0.01 mg mL\(^{-1}\) \(\text{p-H}_8\text{TPPA}\) in the presence (dashed lines) and absence (solid lines) of HAP. The dye was diluted to 0.01 mg mL\(^{-1}\) in PBS (pH 7.4, green), TBS (pH 7.4, orange), HEPES (pH 7.4, purple) and dH\(_2\)O with absorbance and fluorescence spectra obtained using the Flexstation 3 microplate reader.

sponds with the absorbance of the dye in d-DMSO (Figure S16). There is a noticeable shift in the absorbance peak maximum when diluted in dH\(_2\)O, from 415 nm to 435 nm, which suggests a shift in the fluorescent properties of the dye due to protonation. This is also reflected in the maximal peak of the fluorescence intensity (Figure 2B), with a shift from \(\lambda_{em}\) 646–648 nm for PBS, TBS and HEPES to \(\lambda_{em}\) 675 nm when diluted in dH\(_2\)O. The fluorescence intensity of \(\text{p-H}_8\text{TPPA}\) is also substantially increased by 1.8, 2.0, 2.0, and 1.6-fold upon HAP binding of the fluorescent probe \(\text{p-H}_8\text{TPPA}\) in PBS, TBS, HEPES and dH\(_2\)O, respectively (Figure 2B, solid vs. dashed lines). Previously reported bisphosphonate fluorophores had sp\(^2\) aliphatic carbons between the fluorescent core and HAP binding, therefore, such systems merely functioned as fluorescent labels with no change in emission due to HAP binding since they lacked synergistic interaction between the HAP and the fluorescent core. Phosphonic acids that have direct sp\(^2\) bonds to the fluorescent core could extend the conjugation of the fluorescent core to the HAP and thereby could initiate changes in the ground and excited states resulting in quenching or enhancing the fluorescence emission. As seen in Figure 2 (B), upon binding of HAP, \(\text{p-H}_8\text{TPPA}\) produces increased fluorescence supporting this hypothesis; \(\text{p-H}_8\text{TPPA}\) is thus the first example of a single sp\(^2\) bonded phosphonic acid unit targeting HAP in the literature.

Comparable experiments with mouse rib sections were conducted using the isopropyldiester forms \(\text{p-H}_8\text{TPPA-OEt}\) and \(\text{m-H}_8\text{TPPA-OEt}\) (See Scheme 1a and 1c) as stains. We found a complete lack of HAP-associated staining with these compounds suggesting that the interaction of phosphonates with HAP was reduced by the isopropylester groups on the phosphonates, preventing binding and interaction of the fluorescent porphyrin core with the HAP. We also noted that the presence of hydrophobic isopropyl groups dramatically reduced their solubilities in the aqueous.

Aiming to use phenylphosphonic acid functionalized porphyrins in in vivo applications, the negative charge on the deprotonated phosphonate might be a handicap by limiting cell permeability. Optional demasking of phosphonate esters in metabolic surroundings might occur, recreating the metal binding PhPO\(_2\)^\(^2\). This possibility led us to examine \(\text{p-H}_8\text{TPPA}\) and \(\text{p-H}_8\text{TPPA-OEt}\) suitability for in vivo cellular experiments by testing their permeability on proliferating human THP-1 monocytes. The cells were probed with either \(\text{p-H}_8\text{TPPA}\) or \(\text{p-H}_8\text{TPPA-OEt}\) in a HEPES-based buffer containing 0.3 % bovine serum albumin. Albumin binds a wide variety of hydrophobic ligands under physiological conditions, so we assumed an improved solubility/accessibility for the isopropyl diester molecule for cellular uptake. In addition, albumin is a regular component of culture media.

As seen in Figure 3, the fluorescence spectra of \(\text{p-H}_8\text{TPPA}\)-loaded THP-1 cells very much resembles the characteristics of the sensor diluted in HEPES-buffer (see Figure 1A, F). Thus, beyond the low toxicity \(\text{p-H}_8\text{TPPA}\) provides two more positives -cell permeability and cellular retention- desirable for imaging applications. \(\text{p-H}_8\text{TPPA-OEt}\) was much less efficient in labeling the THP-1 cells (see Figure S23). We hypothesize that the phenylphosphonic acid porphyrins, being somewhat amphipathic, were able to penetrate the cell membrane, whereas the more nonpolar esters were not as efficient.

In conclusion, herein, we have reported next-generation fluorescent probes to target calcifications, namely \(\text{p-H}_8\text{TPPA}, \text{m-H}_8\text{TPPA}, \text{p-H}_8\text{TPPA-OEt}\), and \(\text{m-H}_8\text{TPPA-OEt}\) in which the phosphonic acid metal binding unit(s) are exclusively bonded to sp\(^2\) carbon atoms of the fluorescent core. sp\(^2\) bonding of the metal binding unit to the fluorescent core further extended the conjugation of the fluorescent core to the HAP leading to significant increase in fluorescence upon HAP binding. We further used these fluorescent probes to target the HAP in mouse ribs and observed their interaction with human cells. Both \(\text{m-H}_8\text{TPPA}\) and \(\text{m-H}_8\text{TPPA}\) have shown HAP specific binding in rat bone sections. The more protected metal binding nature of the \(\text{m-H}_8\text{TPPA}\) resulted in longer fluorescence period compared to its positional isomer \(\text{p-H}_8\text{TPPA}\). As a control, we have also synthesized phosphonatediesters of the synthesized fluorescent probes, which showed no HAP binding. \(\text{p-H}_8\text{TPPA}\) can travel through the cellular membrane, whereas the pres-
ence of bulky and hydrophobic isopropyl groups in p-H$_4$TPPA-$\text{Pr}_{12}$ hindered their passage through the cellular membrane. This is the first study utilizing sp$^3$-bonded phosphonic acids with the fluorescent cores to target HAP mineralizations. We have shown that compact fluorescent probes with phosphonic acid metal binding group(s) may be used to monitor microlocalizations and calcifications. In addition, their easy acceptance into the cellular matrix indicate that they could be used to target organelle-specific calcifications such as mitochondrial calcifications. The reported low toxicity of p-H$_4$TPPA and the new synthetic methods indicate that they can be used in targeting wide range of calcifications in vivo. We are currently developing our library to target organelle specific calcifications.

Animal Experiments

Animal procedures were approved by Queen’s University Belfast Animal Welfare and Ethical Review Board (AWEB) and authorized under the UK Animals (Scientific Procedures) Act 1986. Animal use conformed to the standards of the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research and with European Directive 210/63/EU.

Acknowledgements

G.Y. would like to thank the DFG for funding his work. C.N.B. would like to thank to Department for Education of Northern Ireland for PhD stipendship and I.L. would like to thank to a research grant from the Belfast Association for the Blind.

Conflict of interest

G.Y. and H.H. have pending patent protecting some of the presented data.

Keywords: Alzheimer’s disease · calcifications · fluorescent imaging · ligand synthesis · vascular calcifications

[1] A. Vallesio-illarramendi, I. Toral-Ojeda, G. Aldanondo, A. López de Munain, Expert. Rev. Mol. Med. 2014, 16, E16.
[2] “Soft Tissue Calcification and Ossification”: A. H. Newberg in Imaging of Arthritis and Metabolic Bone Disease (Ed.: B. N. Weissman), Elsevier, 2009, chap. 39, pp. 681–696.
[3] E. M. Ramos, J. Oliveira, M. J. Sobrido, G. Appolonia, Primary Familial Brain Calcification (Eds.: C. P. Adam, H. H. Arding, R. A. Pagon, S. E. Wallace, L. J. H. Bean, K. Stephens, A. Amemiya), 1993 –2020.
[4] M. G. Pilgrim, I. Lengyel, A. Lanzirotti, M. Newville, S. Fearn, E. Emri, J. C. Knowles, J. D. Messinger, R. W. Read, C. Guidry, C. A. Curcio, Invest. Ophthal. Vis. Sci. 2017, 58, 708–719.
[5] S. M. Nee, N. Chen, J. Am. Soc. Nephrol. 2008, 19, 213 –216.
[6] G. M. Garcia, G. C. McCord, R. Kumar, Semin. Musculoskelet Radiol. 2003, 7, 187–193; b) M. E. Witte, A. M. Schumacher, C. F. Mahler, J. P. Bowersdor, J. L. Ehrlich, A. Schierl, R. Sánchez, R. R. Williams, O. Griesbeck, R. Naumann, T. Misgeld, M. Kerschensteiner, M. Haase, J. Beckmann, CrystEngComm 2016, 20, 2152–2158.
[7] G. S. Mintz, JACC-Cardiovasc. Interv. 2015, 8, 471 –471.
[8] N. B. Senguttuvan, S. Kumar, W.-S. Lee, S. Mishra, H. J. Cho, J. E. Kwon, S. H. Hyeon, Y. S. Jeong, H. Won, S. Y. Shin, K. J. Lee, T. H. Kim, C. J. Kim, S.-W. Kim, Plos One 2016, 11, e0165885.
[9] A. Fatemi-Ardekan, C. Boylan, M. D. Noseworthy, Med. Phys. 2009, 36, 5428–5436.
[10] S. Schwartzenberg, I. V. S. Shapira, M. Vaturi, M. Nasser, I. Yediya, H. Ofek, S. Kazum, D. Monakier, R. Kornowski, A. Sage, Eur. Heart J. Cardiovasc. Imaging 2020, 21, jez319.805.
[11] Y. Wang, M. T. Osborne, B. Tung, M. Li, Y. Li, J. Am. Heart Assoc. 2018, 7, e008564.
[12] J. Rungby, M. Kasmim, E. F. Eriksen, G. Dachsch, Histochim. J. 1993, 25, 446 –451.
[13] A. Bensimun-Brito, J. Cardeia, G. Dionisio, A. Hryusse, M. L. Cancela, F. Witten, BMC Dev. Biol. 2016, 16, 2.
[14] “Red and Near-Infrared Fluorometry”: R. B. Thompson in Topics in Fluorescence Spectroscopy Vol. 4: Probe Design and Chemical Sensing (Eds.: J. R. Lakowicz), 1994, New York, Plenum Press, pp. 151–181.
[15] G. Hong, A. Antarin, H. Dai, Nat. Biomed. Eng. 2017, 1, 0101.
[16] J. R. Coronado, J. R. Heitz, L. Brand, Biochemistry 1990, 29, 1540–1546.
[17] J.-B. LePecq, P. Paletoti, J. Mol. Biol. 1967, 27, 87–106.
[18] G. Yuscesan, Y. Zorlu, M. Stricker, J. Beckmann, Comm. Chem. Rev. 2018, 36, 105–122.
[19] R. von Moos, L. Costa, E. Gonzalez-Suarez, E. Terpos, D. Niepel, J. J. Body, Cancer Treat. Rev. 2017, 75, 57–67.
[20] A. Bulut, M. Maeres, K. Atak, Y. Zorlu, B. Cosut, J. Zubieta, J. Beckmann, Haase, G. Yuscesan, CrystEngComm 2018, 20, 2152–2158.
[21] M. Maeres, M. A. Ayhan, K. B. Yu, A. O. Yazdinyan, K. Harmandar, H. Haase, J. Beckmann, Y. Zorlu, G. Yuscesan, Chem. Eur. J. 2019, 25, 11214–11217.
[22] R. J. Motekaitis, M. C. Metz, A. E. Martell, Inorg. Chem. 1976, 15, 2303–2306.
[23] T. K. Hurst, D. Wang, R. B. Thompson, C. A. Fierke, Biochim. Biophys. Acta Proteins Proteomics 2010, 1804, 393–403.
[24] R. J. Salcedo, M. R. Colodrero, M. Bazaga-Garca, A. Vasileiou, M. Papadaki, P. Oliveria-Pastor, A. Infantes-Molina, E. R. Losilla, G. Mezei, A. Cabeza, K. D. Demadis, CrystEngComm 2018, 20, 7648–7658.
[39] H. Hyun, H. Wada, K. Bao, J. Gravier, Y. Yadav, M. Laramie, M. Henary, J. V. Frangioni, H. S. Choi, Angew. Chem. Int. Ed. 2014, 53, 10668 –10672; Angew. Chem. 2014, 126, 10844 –10848.

[40] K. Nagarajan, K. P. Shelly, R. R. Perkins, R. Stewart, Can. J. Chem. 1987, 65, 1729 –1733.

[41] A. M. Sim, N. A. Rashdan, L. Cui, A. J. Moss, F. Nudelman, M. R. Dweck, V. E. MacKae, A. N. Hulme, Sci. Rep. 2018, 8, 17360.

[42] K. R. Bhushan, E. Tanaka, J. V. Frangioni, Angew. Chem. Int. Ed. 2007, 46, 7969 –7971; Angew. Chem. 2007, 119, 8115 –8117.

[43] S. Sun, K. M. Blazewska, A. P. Kadina, B. A. Kashemirov, X. Duan, J. T. Triffitt, J. E. Dunford, R. Graham, G. Russell, F. H. Ebetino, A. J. Roelofs, F. P. Coxon, M. W. Lundy, C. E. McKenna, Bioconjugate Chem. 2016, 27, 329 –340.

[44] A. Schüttrumpf, A. Duthie, E. Lork, G. Yücesan, J. Beckmann, Z. Anorg. Allg. Chem. 2018, 644, 1134 –1142.

[45] A. Schüttrumpf, E. Kirpi, A. Bulut, F. L. Morel, M. Ranocchiari, E. Lork, Y. Zorlu, S. Grabowsky, G. Yücesan, J. Beckmann, Cyst. Growth Des. 2015, 15, 4925 –4931.

[46] A. Bulut, Y. Zorlu, M. Wörle, S. Paşa, H. Kurt, J. Zubieta, J. Beckmann, G. Yücesan, Eur. J. Inorg. Chem. 2016, 3506 –3512.

[47] A. Bulut, Y. Zorlu, M. Wörle, A. Çetinkaya, H. Kurt, B. Tam, A. Özgür Yazaydın, J. Beckmann, G. Yücesan, ChemistrySelect 2017, 2, 7050 –7053.

[48] T. Rhauderwiek, H. Zhao, P. Hirschle, M. Döblinger, B. Bueken, H. Reinsch, D. De Vos, S. Wuttke, U. Kolb, N. Stock, Chem. Sci. 2018, 9, 5467 –5478.

Manuscript received: April 3, 2020
Accepted manuscript online: April 15, 2020
Version of record online: July 28, 2020